1. Scrip
  2. >>New Products

J&J Hits Another Myeloma Milestone With FDA Approval Of Talvey

First Approved GPRC5D-Directed Therapy

 
• By Alaric DeArment

The approval gives the company’s products a key presence in the myeloma space from the point of diagnosis and into later lines of disease.

J&J got another first in myeloma, this time with the approval of a GPRC5D-directed bispecific antibody • Source: Shutterstock

Johnson & Johnson’s Janssen Pharmaceutical Cos. has further strengthened its market position in the treatment of multiple myeloma with the US Food and Drug Administration accelerated approval of Talvey (talquetamab-tgvs) as the first approved GPRC5DxCD3-targeting bispecific antibody to treat the disease. In addition to being the third first-in-class myeloma drug from Janssen to win approval, Talvey also means the drug maker has options for treatment from the time of diagnosis all the way through later lines of therapy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: 13 Approvals And 13 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.